New Delhi: Trials are still on, but it seems more and more certain that a booster dose of COVID-19 vaccine will be recommended before long.
The Financial Times reported that a study has found a third booster dose of the Oxford-AstraZeneca vaccine, which is being manufactured by the name of Covishield in India, works well in tackling novel coronavirus disease.
FT quoted a source as saying that the yet-to-be-published research has found the booster dose enhances antibodies in a person against the coronavirus spike protein.
Significantly, the booster shot led to an antibody reaction that was “strong enough to tackle any variant” of the coronavirus that causes the COVID-19 disease.
It’s not clear when the findings of the study, which has been conducted by Oxford University, will be released officially.
The Oxford-AstraZeneca vaccine is currently administered in two doses, at a gap of eight weeks in the UK and between 12-16 weeks in India.
Drugs Controller General of India (DCGI) has permitted Bharat Biotech to trial a third booster dose of its vaccine Covaxin.
New Delhi: After Diljit Dosanjh called out the double standards of Telangana government for banning…
New Delhi: Recent actions and counter-actions in the Russia-Ukraine conflict have pushed the world to the…
Balangir: Three persons were arrested and fake IPS officers’ uniforms along with fake identity cards…
Mumbai: Abhishek Bachchan’s highly-anticipated film ‘I Want To Talk’ released in theatres on Friday, and the…
New Delhi: Accused of giving cash to secure votes ahead of election day in Maharashtra,…
Bhubaneswar: Chief Minister Mohan Charan Majhi attended the ‘Odisha State Day Celebrations’ at the 43rd…
Mumbai: Recently, some morphed pictures of actress Shweta Tiwari and her good friend Vishal Aditya…
Phulbani: Two tribal men were sentenced to life imprisonment by a special court in Odisha's…